Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 2
2008 2
2009 2
2010 4
2011 3
2012 2
2013 5
2014 5
2015 3
2016 3
2017 4
2018 5
2019 5
2020 6
2021 11
2022 12
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. Cappellini MD, et al. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. N Engl J Med. 2020. PMID: 32212518 Clinical Trial.
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators. Taher AT, et al. Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22. Lancet Haematol. 2022. PMID: 36007538 Clinical Trial.
Development of a Thalassemia International Prognostic Scoring System (TIPSS).
Vitrano A, Musallam KM, Meloni A, Karimi M, Daar S, Ricchi P, Costantini S, Vlachaki E, Di Marco V, El-Beshlawy A, Hajipour M, Ansari SH, Filosa A, Ceci A, Singer ST, Naserullah ZA, Pepe A, Cademartiri F, Pollina SA, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A; International Working Group on Thalassemia (IWG-THAL). Vitrano A, et al. Among authors: ricchi p. Blood Cells Mol Dis. 2023 Mar;99:102710. doi: 10.1016/j.bcmd.2022.102710. Epub 2022 Nov 25. Blood Cells Mol Dis. 2023. PMID: 36463683 Review.
Thalassemia and hepatocellular carcinoma: links and risks.
Marsella M, Ricchi P. Marsella M, et al. Among authors: ricchi p. J Blood Med. 2019 Sep 17;10:323-334. doi: 10.2147/JBM.S186362. eCollection 2019. J Blood Med. 2019. PMID: 31572038 Free PMC article.
Bone status and HCV infection in thalassemia major patients.
Meloni A, Pistoia L, Maffei S, Ricchi P, Casini T, Corigliano E, Putti MC, Cuccia L, Argento C, Positano V, Pepe A, Cademartiri F, Vassalle C. Meloni A, et al. Among authors: ricchi p. Bone. 2023 Apr;169:116671. doi: 10.1016/j.bone.2023.116671. Epub 2023 Jan 6. Bone. 2023. PMID: 36623757
Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia.
Musallam KM, Vitrano A, Meloni A, Pollina SA, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Ansari SH, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A; International Working Group on Thalassemia (IWG-THAL). Musallam KM, et al. Among authors: ricchi p. Am J Hematol. 2022 Feb 1;97(2):E78-E80. doi: 10.1002/ajh.26428. Epub 2021 Dec 10. Am J Hematol. 2022. PMID: 34862982 Free article. No abstract available.
The use of hydroxyurea in the real life of MIOT network: an observational study.
Ricchi P, Meloni A, Rigano P, Pistoia L, Spasiano A, Allò M, Messina G, Quarta A, Rosso R, Quota A, Filosa A, Maggio A, Pepe A. Ricchi P, et al. Expert Opin Drug Saf. 2022 Nov;21(11):1433-1440. doi: 10.1080/14740338.2022.2064980. Epub 2022 Apr 17. Expert Opin Drug Saf. 2022. PMID: 35435090
78 results